Drug Search Results
More Filters [+]

Garetosmab

Alternative Names: garetosmab, regn-2477, regn2477, regn 2477
Latest Update: 2024-11-19
Latest Update Note: Clinical Trial Update

Product Description

Garetosmab is a VelocImmune-derived fully-human monoclonal antibody that binds and neutralizes Activin A, which is involved in the development of heterotopic bone in people with FOP. Garetosmab is currently being studied in adults with FOP. (Sourced from: https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-encouraging-garetosmab-phase-2-results#:~:text=Garetosmab%20is%20a%20VelocImmune%2Dderived,studied%20in%20adults%20with%20FOP.)

Mechanisms of Action: TGFb Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Regeneron
Company Location: TARRYTOWN NY 10591
Company CEO: Leonard S. Schleifer
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Garetosmab

Countries in Clinic: Australia, Brazil, Canada, Chile, China, Colombia, Finland, France, Hong Kong, Italy, Japan, Korea, Malaysia, Netherlands, Poland, Puerto Rico, South Africa, Spain, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 5

Highest Development Phases

Phase 3: Fibrodysplasia Ossificans Progressiva|Myositis Ossificans

Phase 2: Obesity

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

R2477-FOP-2175

P3

Unknown Status

Fibrodysplasia Ossificans Progressiva

2026-09-29

OPTIMA

P3

Active, not recruiting

Fibrodysplasia Ossificans Progressiva

2026-04-26

jRCT2041220096

P3

Recruiting

Fibrodysplasia Ossificans Progressiva

2026-03-31

COURAGE

P2

Recruiting

Obesity

2026-02-16

Recent News Events